Schedule 13D ownership disclosure
Gemini Therapeutics, Inc. /DE
Security class unavailable · CUSIP: 36870G105
Event date: 2022-09-28
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 5.7800%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-22-004509
- Form type
- SC 13D
- Filer
- ADAGE CAPITAL PARTNERS GP, L.L.C.
- CIK
- CIK 1165408
- Filed
- Oct 11, 2022
- Reporting period
- Sep 28, 2022
- Description
- Schedule 13D beneficial ownership